A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia.
Stroke research has endured many setbacks in translating neuroprotective therapies into clinical practice. In contrast, the real-world therapy (tPA thrombolysis) rarely produces benefits in mechanical occlusion-based experimental models, which dominate preclinical stroke research. This split between the bench and bedside suggests the need to employ tPA-responsive models in preclinical stroke research. To this end, a simple and tPA-reactive thrombotic stroke model is invented and described here. This model consists of transient occlusion of the unilateral common carotid artery and delivery of 7.5% oxygen through a face mask in adult mice for 30 min, while maintaining the animal rectal temperature at 37.5 ± 0.5 °C. Although reversible ligation of the unilateral carotid artery or hypoxia each suppressed cerebral blood flow only transiently, the combination of both insults caused lasting reperfusion deficits, fibrin and platelet deposition, and large infarct in the middle cerebral artery-supplied territory. Importantly, tail-vein injection of recombinant tPA at 0.5, 1, or 4 hr post-tHI (10 mg/kg) provided time-dependent reduction of the mortality rate and infarct size. This new stroke model is simple and can be standardized across laboratories to compare experimental results. Further, it induces thrombosis without craniectomy or introducing pre-formed emboli. Given these unique merits, the tHI model is a useful addition to the repertoire of preclinical stroke research.
Department of Pediatrics, Division of Neurology, The Emory University School of Medicine.
Yu-Yo
YY
Sun
Department of Pediatrics, Division of Neurology, The Emory University School of Medicine; alex.kuan@emory.edu.
Chia-Yi
CY
Kuan
D000818:Animals; D004195:Disease Models, Animal; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D020925:Hypoxia-Ischemia, Brain / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D002546:Ischemic Attack, Transient / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage
D010959:Tissue Plasminogen Activator